Efficacy of Intravitreal Bevacizumab versus Intravitreal Triamcinolone for treatment of Uveitic Macular Edema in tertiary care hospital of Jharkhand

Abstract

Background: Uveitic macular edema is most common cause of visual impairment in both infectious and non-infectious uveitis. It accounts for more than 30% cases of active uveitis. Purpose: To compare the effects of Intravitreal injections of Bevacizumab and Triamcinolone for the treatment of Cystoid macular edema in non-infectious uveitis. Methods: 40 eyes of 35 consecutive patients with CME associated with non-infectious uveitis were divided to 2 groups. 20 eyes were treated with 1.25mg of IVB and 20 eyes received 4mg of IVT. The clinical course of Best corrected visual acuity, Intraocular pressure and Central macular thickness by Optical Coherence Tomography was monitored for up to 6 months after the initial injection. Results: The best visual acuities were achieved 1 month after injection in both groups. In IVB group improvement in Visual acuitywas achieved in 16/20(80%) of eyes and in IVT group was 19/20(95%). In IVT group intraocular pressure was found to be raised. The Central macular thickness reduction in the IVT group wasfrom 298.52μ to 197.68μ and in IVB group was from 311.76μ to 227.13μ. Conclusion: Both IVB and IVT treatments can effectively improve Best corrected visual acuity and reduce Central macular thickness in Uveitic Cystoid macular edema patients. The Central macular thickness reduction was greater in IVT groupthan IVB group. The IVT group causes increase in intraocular pressure.